荃信生物-B(02509)2025年收入激增逾4倍经调整溢利约3.56亿元同比扭亏为盈

智通财经03-27

智通财经APP讯，荃信生物-B(02509)公布2025年业绩，收入约8.07亿元，同比增长约4.08倍;毛利约7.14亿元，同比增长约6.75倍;研发开支约2.53亿元，同比减少24.26%;年内溢利3.07亿元，经调整年内溢利约3.56亿元，同比扭亏为盈;每股盈利1.41元。公告称，收入主要来自(i)主要与QX030N及QX031N的对外授权交易有关的对外授权收入增加6.225亿元;(ii)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622824136?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-27 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622824136","market":"sh","top_or_hot":-1,"title":"荃信生物-B(02509)2025年收入激增逾4倍 经调整溢利约3.56亿元 同比扭亏为盈","media":"智通财经","content":"<div>\n<p>智通财经APP讯，荃信生物-B(02509)公布2025年业绩，收入约8.07亿元，同比增长约4.08倍;毛利约7.14亿元，同比增长约6.75倍;研发开支约2.53亿元，同比减少24.26%;年内溢利3.07亿元，经调整年内溢利约3.56亿元，同比扭亏为盈;每股盈利1.41元。公告称，收入主要来自(i)主要与QX030N及QX031N的对外授权交易有关的对外授权收入增加6.225亿元;(ii)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420852.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荃信生物-B(02509)2025年收入激增逾4倍 经调整溢利约3.56亿元 同比扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荃信生物-B(02509)2025年收入激增逾4倍 经调整溢利约3.56亿元 同比扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 20:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1420852.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，荃信生物-B(02509)公布2025年业绩，收入约8.07亿元，同比增长约4.08倍;毛利约7.14亿元，同比增长约6.75倍;研发开支约2.53亿元，同比减少24.26%;年内溢利3.07亿元，经调整年内溢利约3.56亿元，同比扭亏为盈;每股盈利1.41元。公告称，收入主要来自(i)主要与QX030N及QX031N的对外授权交易有关的对外授权收入增加6.225亿元;(ii)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420852.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1420852.html","article_id":"2622824136","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622824136","pubTimestamp":1774616381,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，荃信生物-B 公布2025年业绩，收入约8.07亿元，同比增长约4.08倍;毛利约7.14亿元，同比增长约6.75倍;研发开支约2.53亿元，同比减少24.26%;年内溢利3.07亿元，经调整年内溢利约3.56亿元，同比扭亏为盈;每股盈利1.41元。截至最后实际可行日期，公司已有一款商业化产品，即国内首个乌司奴单抗生物类似药赛乐信，其2025年国内销售额近3亿元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"Tsuen Xin Bio-B (02509) revenue surged more than 4 times in 2025, adjusted profit turned from loss to profit of approximately 356 million yuan year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1.5},"content_text":"智通财经APP讯，荃信生物-B(02509)公布2025年业绩，收入约8.07亿元，同比增长约4.08倍;毛利约7.14亿元，同比增长约6.75倍;研发开支约2.53亿元，同比减少24.26%;年内溢利3.07亿元，经调整年内溢利约3.56亿元，同比扭亏为盈;每股盈利1.41元。公告称，收入主要来自(i)主要与QX030N及QX031N的对外授权交易有关的对外授权收入增加6.225亿元;(ii)研发服务收入增加1670万元，主要由于CDMO服务增长3550万元，部分被QX004N及QX008N临床服务费减少所抵销;及(iii)赛乐信®的供应增加900万元，与赛乐信®的销售增长一致。截至最后实际可行日期，公司已有一款商业化产品，即国内首个乌司奴单抗生物类似药赛乐信®，其2025年国内销售额(含增值税)近3亿元。两款核心产品研发进展顺利，奥托奇拜单抗(IL-4Rα单抗)在中国针对结节性痒疹(PN)及特应性皮炎(AD)的III期临床试验已达到主要终点，这两项适应症的新药上市申请(NDA)预期将于年内陆续提交。鲁塞奇塔单抗(IL-17A单抗)用于强直性嵴柱炎(AS)的新药上市申请已获受理。QX004N(IL-23p19单抗)及QX008N(TSLP单抗)在国内分别处于银屑病(Ps)及慢性阻塞性肺病(COPD)III期临床试验，合作伙伴正在加速开发。随着公司的单抗产品逐步迈向商业化阶段，公司的发展前景持续向好，“荃信1.0”布局已接近完成。此外，基于在自免领域的深厚积累，公司高效开发了一系列长效双抗管线，在保持皮肤科优势的同时，深入探索唿吸系统疾病等领域的重大潜在机遇。公司与CalderaTherapeutics、罗氏及WindwardBio的接连合作，展示了公司在推进全球策略方面的执行能力。随着QX030N(IL-23p19/TL1A双抗)、QX031N(TSLP/IL-33双抗)及QX027N(TSLP/IL-13双抗)逐步进入临床阶段，“荃信2.0”迭代正全速启航。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622824136","isCrawlerRequest":true}

荃信生物-B(02509)2025年收入激增逾4倍 经调整溢利约3.56亿元 同比扭亏为盈

精彩评论

荃信生物-B(02509)2025年收入激增逾4倍经调整溢利约3.56亿元同比扭亏为盈